Does CASIMERSEN Cause Infusion site extravasation? 10 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Infusion site extravasation have been filed in association with CASIMERSEN (AMONDYS 45). This represents 1.3% of all adverse event reports for CASIMERSEN.
10
Reports of Infusion site extravasation with CASIMERSEN
1.3%
of all CASIMERSEN reports
0
Deaths
0
Hospitalizations
How Dangerous Is Infusion site extravasation From CASIMERSEN?
Of the 10 reports.
Is Infusion site extravasation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CASIMERSEN. However, 10 reports have been filed with the FAERS database.
What Other Side Effects Does CASIMERSEN Cause?
Product dose omission issue (253)
No adverse event (166)
Poor venous access (101)
Device issue (76)
Intentional dose omission (74)
Malaise (36)
Pyrexia (31)
Covid-19 (29)
Influenza (18)
Pneumonia (17)
What Other Drugs Cause Infusion site extravasation?
HUMAN IMMUNOGLOBULIN G (822)
INFLIXIMAB (435)
INFLIXIMAB-DYYB (328)
TREPROSTINIL (256)
VEDOLIZUMAB (199)
HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN (185)
REMDESIVIR (144)
FERRIC CARBOXYMALTOSE (118)
RITUXIMAB (82)
NATALIZUMAB (70)
Which CASIMERSEN Alternatives Have Lower Infusion site extravasation Risk?
CASIMERSEN vs CASIRIVIMAB
CASIMERSEN vs CASIRIVIMAB\IMDEVIMAB
CASIMERSEN vs CASPOFUNGIN
CASIMERSEN vs CATEQUENTINIB
CASIMERSEN vs CC-4047